ClinicaliQ Trial Snapshot
- Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) — Active Not Recruiting • Phase III • Oncology • NCT04704934.
- DESTINY-Gastric04 Summary.
- Trastuzumab deruxtecan improves survival compared with ramucirumab plus paclitaxel in HER2-positive gastric cancer after trastuzumab treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy. Conditions: Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Interventions: Trastuzumab deruxtecan, Ramucirumab, Paclitaxel Lead Sponsor: Daiichi Sankyo Planned Enrollment: 490 participants